Mycobacterium bovis infection of cattle and other domesticated animals exacts a significant economic toll in both economically developing and industrialized countries. Vaccination of herds and/or wild animals that share their grazing land and serve as reservoirs of infection has been proposed as a strategy to combat bovine tuberculosis. However, the only currently available vaccine, M. bovis BCG, is not highly efficacious. Here we show that a live recombinant vaccine, rBCG30, which expresses large amounts of the Mycobacterium tuberculosis 30 kDa major secretory protein, is more efficacious against bovine tuberculosis than BCG in the highly demanding guinea pig model of pulmonary tuberculosis. 
1.

Introduction
Tuberculosis in humans caused by Mycobacterium bovis, the agent of tuberculosis in cattle, has been reduced to low levels in industrialized countries as a result of milk pasteurization and animal tuberculosis control programs.
However, in economically developing countries, where pasteurization is only sporadically practiced and animal tuberculosis control programs are frequently suboptimal or nonexistent, bovine (i.e. M. bovis -caused) tuberculosis in humans remains a substantial public health problem [1] .
M. bovis infection of domesticated animals, especially cattle, exacts a significant economic toll in both developing and industrialized countries. M. bovis has one of the broadest host ranges of all pathogens; it has been found in over 20 animal species [2] . In cattle, the infection reduces milk production, the food value of the meat, and fertility; the economic losses have been conservatively estimated to exceed $3 billion annually [3] . Control measures, where they can be afforded, require extensive testing of herds and slaughter of infected animals to prevent bovine-to-human transmission [3] . Complicating the control of M. bovis infection, wild animals infected with M. bovis frequently serve as reservoirs for infecting the domesticated animals. Such wild animals include the badger in the United Kingdom and Ireland, the bushtail possum in New Zealand, the whitetailed deer in the United States, the marsh antelope in Zambia, and the African buffalo in South Africa [2, [4] [5] [6] [7] .
Vaccination of herds and/or wild animals that share their grazing land has been proposed as a viable strategy for augmenting the control of tuberculosis in cattle [1, 8] . Vaccination of herds may be a particularly attractive option in settings where the culling of animals presents an economic hardship.
Vaccination of wild animal reservoirs may be a more effective control measure, and one more acceptable to animal conservationists, than culling these animals to control tuberculosis in cattle. Culling wild animals to control cattle tuberculosis has met with mixed success [9] ; in Great Britain, where the incidence of cattle tuberculosis has soared in recent decades, culling of badgers may actually have increased the incidence of bovine tuberculosis in cattle [10] .
The attenuated M. bovis strain Bacille Calmette-Guérin or BCG, widely used as a vaccine against Mycobacterium tuberculosis in humans, has been tested as a vaccine against bovine tuberculosis. Its efficacy against M. bovis infection in cattle in field trials has been inconsistent and generally poor (<50%)¸ not unlike its efficacy against human tuberculosis, primarily caused by M. tuberculosis [11] .
Hence, a more potent vaccine against M. bovis infection is needed.
We have previously described a live recombinant BCG vaccine, rBCG30, that is significantly more potent than BCG in protecting against M. tuberculosis aerosol challenge in the guinea pig model of pulmonary tuberculosis [12, 13] .
This animal model is noteworthy among small animal models for its high susceptibility to both M. tuberculosis and M. bovis infection and for the close clinical, immunological and pathological resemblance of tuberculosis in this species to tuberculosis in humans and cattle. rBCG30 expresses large amounts of the M. tuberculosis 30 kDa major secretory protein, a mycolyl transferase [12] .
In each of eight consecutive experiments, guinea pigs vaccinated with rBCG30 and challenged 10 weeks later with M. tuberculosis by aerosol had significantly fewer CFU in their lungs and spleens 10 weeks after challenge than guinea pigs immunized with the parental strain of BCG (on average 0.75 ± 0.1 log fewer CFU in the lungs and 1.1 ± 0.1 log fewer CFU in the spleens; n = 178 BCG-immunized animals and n = 179 rBCG30-immunized animals; P<<0.0001). Moreover, compared with BCG-immunized animals, who were highly protected compared with sham-immunized animals, rBCG30-immunized animals had ~10-fold fewer lung lesions, significantly less lung pathology, and significantly longer survival after M. tuberculosis aerosol challenge [12, 13] . rBCG30 is currently in human clinical trials.
In this study, we have explored the potential for rBCG30 as a vaccine against bovine tuberculosis by studying its efficacy in protecting against M. bovis aerosol challenge in the outbred guinea pig model of pulmonary tuberculosis. 
Materials and methods
Vaccines and challenge strain
The vaccines tested were the parental Mycobacterium bovis BCG Tice (BCG), rBCG30 (pSMT3-MTB30 or pMTB30) Tice [12] , and rBCG30Mb (pSMT3-MB30) Tice, a recombinant BCG Tice expressing large amounts of the homologous M. The challenge strain was the Mycobacterium bovis Type strain (ATCC 19210), prepared as described for M. tuberculosis in previous studies [12] .
Immunization of guinea pigs
Specific-pathogen free 250-to 300-g outbred male Hartley strain guinea pigs from Charles Rivers Breeding Laboratories were injected intradermally with 10 3 CFU of parental BCG, rBCG30, or rBCG30Mb prepared as previously described [12, 13] . The preparation of the vaccines entailed washing the bacteria by centrifugation, enumerating them in a Petroff-Hausser chamber, and resuspending them in phosphate-buffered saline (PBS); such bacteria had a very high (>90%) CFU:particle ratio. Control animals were sham-immunized with buffer (PBS) only. For studies of cutaneous delayed-type hypersensitivity (DTH), guinea pigs were immunized in groups of 6 animals each. For studies of protective immunity, separate guinea pigs were immunized in groups of 15 animals each except for sham-immunized animals (9 per group). Separate groups of animals were studied in the protection experiments to eliminate the possibility that skin-testing might influence the results by boosting immunoprotection [14] . All animal experiments were approved by the Chancellor's Animal Research Committee at UCLA.
Cutaneous DTH and antibody titer
Guinea pigs were shaved over the back and injected intradermally with 10 µg of the M. tuberculosis 30 kDa major secretory protein (r30) in 100 µl PBS. r30 was purified as described from culture filtrates of recombinant Mycobacterium smegmatis 1-2c containing plasmid pMTB30 and demonstrated to be indistinguishable from the native protein [15, 16] . The extent (diameter) of induration was assessed 24 hr later by palpation and inspection in direct and oblique light.
Immediately after the skin test was read, we euthanized a subset of 4 of the 6 animals and assayed their serum for antibody titer to r30 by ELISA, using Costar 
Protective immunity to aerosol challenge
Ten weeks after the guinea pigs were immunized, the animals were challenged with an aerosol generated from a single cell suspension of M. bovis.
In Experiments 1, 2, and 3, the animals received a high (~20 live bacteria), medium (~10 live bacteria), and low (~5 live bacteria) dose, respectively, of bacteria into the lungs, based on counting primary lesions in the lungs of animals euthanized three weeks after exposure to aerosols generated from bacterial 6 suspensions in the range of concentrations used in this study. Afterwards, guinea pigs were individually housed in stainless steel cages contained within a laminar flow biohazard safety enclosure and allowed free access to standard laboratory food and water. The animals were observed for illness and weighed weekly for 10 weeks and then euthanized. The lungs, spleen, and liver of each animal were removed aseptically, and the right lung and spleen were cultured for CFU of M. bovis as described for culturing M. tuberculosis in previous studies [12, 13] . The liver was inspected visually and the extent of involvement with tuberculosis was graded using a scale of 0-4 where 0, 0.5, 1, 1.5, 2, 2.5, and 3 were assigned livers with 0, 1-9, 10-19, 20-39, 40-59, 60-79, and 80-120 surface lesions, respectively; 3.5 was assigned livers with 100-200 surface lesions including coalescent lesions; and 4 was assigned livers with >200 lesions.
Statistics
Parametric analysis of variance (ANOVA) and non-parametric Kruskal-Wallis Table 1 ). rBCG30 and rBCG30Mb-immunized animals also had greater antibody responses to the 30 kDa protein than BCG-immunized animals ( Fig. 2) , differences that were statistically significant (P ≤ 0.03 by ANOVA or K-W for animals immunized with BCG vs. either rBCG30 or rBCG30Mb; Table 1 ). In both experiments, the humoral immune response of the BCG-immunized animals to r30 was not significantly greater than that of the sham-immunized animals, as previously observed [14] .
rBCG30 and rBCG30Mb-immunized animals exhibit greater protective immunity to M. bovis aerosol challenge than BCG-immunized animals
To assess the capacity of rBCG30 and rBCG30Mb to induce immunoprotection against M. bovis, 10 weeks after immunization, we challenged immunized and control animals by aerosol with the highly virulent M. bovis Type strain and monitored the subsequent course of infection for 10 weeks. We immunized animals as in the studies of cutaneous DTH and antibody responses described above, except that we used different animals to eliminate the possibility that the skin test itself might influence the result. In addition, we studied much larger numbers of animals per group so as to obtain more reliable data on the burden of M. bovis in animal organs, which preliminary studies showed can vary over a relatively wide range in outbred guinea pigs. We Table 2 ).
Differences between rBCG30-immunized animals and sham-immunized animals were of course even greater than between rBCG30-and BCGimmunized animals, averaging 1.3 ± 0.2 logs in the lung and 2.4 ± 0.4 logs in the spleen in the three experiments, differences which were highly significant ( Table   2 ).
At necropsy, in addition to culturing the lung and spleen for M. bovis, we graded the extent of liver pathology using a scale of 0-4, as described in bovis strains generally are more virulent for guinea pigs than the human-adapted M. tuberculosis strains [17] [18] [19] . Because of the severity of the M. bovis challenge in Experiment 1, we lowered the challenge doses in Experiments 2 and 3 with the result that the immunized animals were better protected by the vaccines administered. This suggests that the high challenge dose of M. bovis in Experiment 1 was so severe that it partially overwhelmed the capacity of the immune system to defend the host. We observed a similar phenomenon in a previous study of immunoprotection against the intracellular bacterial lung pathogen Legionella pneumophila. In that study, guinea pigs immunized by sublethal infection with L. pneumophila and then challenged by aerosol with a 100% lethal dose (LD 100 ) of wild-type L. pneumophila or 2-fold the LD 100 were highly protected from death whereas guinea pigs challenged with 10-fold the LD 100 were either not protected or weakly protected [20] .
As a live mycobacterial vaccine against bovine tuberculosis in animals, rBCG30 has several advantages. First, the vaccine is inexpensive to manufacture, an important consideration in the animal husbandry industry.
Second, the vaccine is relatively easy to administer, requiring only a single injection. Third, the vaccine has been found safe both in small animals (guinea pigs and mice) and in humans in a Phase 1 study. In three animal species, the safety of rBCG30 appears comparable to BCG, which has a very well established safety profile, as over 4 billion doses have been administered to humans since the vaccine was developed nearly a century ago. Review Group in its report to the British government [8] .
Several new generation vaccines have been developed and tested for their capacity to induce protective immunity against M. bovis challenge in various animal models. These include a leucine auxotroph of BCG [24] , a nutritionally impaired avirulent mutant of M. bovis [25] , DNA vaccines [26, 27] and primeboost vaccines utilizing DNA vaccines as the prime and BCG, attenuated M.
bovis, or a protein vaccine as a boost [28] [29] [30] . None of these vaccines were significantly more potent than BCG and some were less potent, including a DNA 13 vaccine that was found to be equivalent to BCG in an inbred mouse model but clearly inferior to BCG in the more stringent guinea pig model [26, 27] . The most impressive vaccine regimens reported have utilized a DNA prime or a prime comprising M. bovis culture filtrate in a CpG oligodeoxynucleotide-containing adjuvant and a BCG boost; these prime-boost vaccine regimens showed a trend toward improvement over BCG in several parameters studied in cattle [29, 31] .
The leucine auxotroph, while inferior to BCG in efficacy, offered the advantage of not sensitizing guinea pigs to tuberculin [24] . Immediately after the skin test was read in the animals described in Fig. 1, three or four of the animals in each group were euthanized and their serum assayed for antibody titer to r30 by ELISA. Data are the reciprocal antibody titer for each individual animal (closed circles) and the geometric mean titer (bar) for each group. For statistical purposes, titers of <125 are scored as 125. At the end of the 10-week observation period, the challenged animals described in Fig. 3 were euthanized and CFU of M. bovis in the lung and spleen were assayed. Data are the mean ± SE for all animals in a group. In Experiment 3, in which the lower limit of detection was 1.0 log/organ, some animals in the BCGand rBCG30-immunized groups had no detectable CFU. In the lung, 2 BCG-immunized and 4 rBCG30-immunized animals, and in the spleen, 4 BCGimmunized and 9 rBCG30-immunized animals had zero CFU detected and were scored at the lower limit of detection for statistical purposes.
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